刘昌孝院士
中国工程院院士、研究员、博士研究生导师。2019年10月获得湖南中医药大学名誉博士。现任威尼斯送彩金28名誉院长、终身首席科学家和学术委员会主任，释药技术与药代动力学国家重点实验室主任，中国-东盟传统药物研究国际合作联合实验室主任，国务院发展中心健康中国促进网中医药院士专家中心主任、国家科技奖励评审专家、国家药监局中药监管科学研究中心专家委员会主任、中国药典委员会顾问、中国药学会常务理事、中国医学科学院学部委员、中国中医科学院学部委员和执行委员、国际药物代谢研究会中国办事处主任、国家药品监督管理局仿制药一致性评价专家委员会副主任、天津市药学会会长、天津市药品监管科学研究会理事长、天津学会学研究会名誉理事长。
刘昌孝院士是我国药代动力学的学科开拓者和学科带头人之一，从事药理学、药代动力学、现代中药和中药质量研究50余年，近十年致力于生物医药发展战略研究，承担和参与多项生物医药战略咨询研究项目。承担过包括国家“973”和“863”项目、国家科技部国际合作项目、国家重大专项课题、国家自然科学基金重点项目等国家重大研究项目50余项，发表论文600多篇，在国内外出版中英文学术专著38部。曾获得国务院特殊津贴(1992)，香港紫荆花医学成就奖（2000），香港紫荆花医学创新金奖（2000），天津市劳动模范（2000），全国劳动模范（2005），全国优秀科技工作者（2012），国际药物代谢研究会“特别贡献奖”（2013），天津市滨海科技突出成就奖（2016），中国药学会突出贡献奖（2017），世界中医药联合会中药分析与标准“终身成就奖”（2018），循证中医药研究“终身成就奖”（2020）、“卓越贡献奖”（2021），光华工程科技特别贡献奖（医药卫生学部全体院士，2020），中国药学会“最美科技工作者”称号（2021），国家科技进步奖二等奖（第一完成人，2020）。
Prof. Chang-xiao Liu, academician of Chinese Academy of Engineering, and doctoral supervisor. Prof. Liu has got honorary doctorate from Hunan University of Chinese Medicine in October 2019. Now, he is the honorary president, tenured chief scientist and academic director of committee of Tianjin Institute of Pharmaceutical Research; In addition, Prof. Liu acts as director of State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, director of China-ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research, director of Academician Expert Center of Health China Promotion Network of Development Research Center of the State Council, evaluation experts of national science and technology award, director of Expert Committee of Chinese Medicine Regulatory Scientific Research Center of National Medical Products Administration, advisor of Chinese Pharmacopoeia Commission, executive director of Chinese Pharmaceutical Association, department members of Chinese Academy of Medical Sciences, department member and executive member of China Academy of Chinese Medical Sciences, director of China Office of International Society of Drug Metabolism, deputy director of Experts Committee on Generic Drug Conformity Evaluation of National Medical Products Administration, chair of Tianjin Pharmaceutical Society, president of Tianjin Drug Regulatory Scientific Research Society, honorary president of Tianjin Society Research Institute.
Prof. Liu is the trailblazer and leader of pharmacokinetics in China, who dedicated his life to pharmacology, pharmacokinetics, modern Chinese medicine research, Chinese medicine quality research for more than 50 years. He has undertaken a number of national scientific research projects. In the past ten years, he has been committed to biomedical development strategy research, and has undertaken and participated in a number of biomedical strategic consulting and research projects. He has undertaken more than 50 national key research projects, including national “973” and “863” projects, international cooperation projects of the Ministry of Science and Technology, national major special projects, and key projects of the National Natural Science Foundation of China. He has published more than 600 academic papers and 38 academic monographs in Chinese and English at home and abroad. Prof. Liu was awarded with the special allowance of the State Council in 1992. He was nominated and awarded as Hong Kong Bauhinia Medical Achievement Award and Gold Award for Medical Innovation in 2000. He has got the titles of Tianjin Model Worker (2020), National Model Worker (2005), National Outstanding Scientific and Technological Researchers (2012), Special Contribution Award of International Society of Drug Metabolism (2013), Tianjin Binhai Science and Technology Outstanding Achievement Award (2016), Outstanding Contribution Award of Chinese Pharmaceutical Society (2017), Life Achievement Award of WTCMS (2018), Life Achievement Award (2020) and Outstanding Contribution Award (2021) of Evidence-based TCM Research, Special Contribution Award for Guanghua Engineering Science and Technology (2020), “Most Beautiful Scientist” title of Chinese Pharmaceutical Association (2021). He gained the second prize of National Scientific and Technological Progress Award as the first accomplisher in 2020.